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Essentials
• The knowledge of quality and safety of acenocoumarol
and phenprocoumon use in children is limited.
• We used data from a multicenter retrospective follow-
up study in children in the Netherlands.
• The quality of anticoagulation control in the first
month of use was low, but improved thereafter.
• No thromboembolic events occurred, however bleeding
events occurred in 1–3 out of 10 patients.
Summary. Background: The use of vitamin-K antagonists
in pediatric patients is rare and information on the qual-
ity and safety of treatment with acenocoumarol and
phenprocoumon is limited. Objectives: To assess the qual-
ity, safety and effectiveness during the first year of aceno-
coumarol and phenprocoumon treatment in pediatric
patients in the Netherlands. Methods: The Children Anti-
coagulation and Pharmacogenetics Study (CAPS) was
designed as a multicenter retrospective follow-up study.
Patients who used acenocoumarol or phenprocoumon at
an age of ≤ 18 years, were selected from four pediatric
hospitals and one anticoagulation clinic in the Nether-
lands. The quality of treatment was assessed by calculat-
ing the percentage of time in therapeutic INR range
(TTR) for the first month and for every 3 months of use
during the first year of treatment. Effectiveness and safety
were assessed by the number of thromboembolic and
bleeding events. Results: In total, 213 patients partici-
pated, of whom 187 (155 acenocoumarol; 32 phenpro-
coumon) were included in this analysis. The mean TTR
was 47.0% and 51.4% in the first month of use for
acenocoumarol and phenprocoumon, respectively. After
the first 3 months the mean TTR for both VKAs was
above 64%. In 14.6% (acenocoumarol) and 31.3% (phen-
procoumon) of the patients a bleeding event occurred
during the first year of treatment; no thromboembolic
events were reported. Conclusions: The quality of antico-
agulation treatment was low during the first month of use
and leaves room for improvement. After the first month
it increased to an acceptable level. However, bleeding
events occurred frequently during the first year.
Keywords: acenocoumarol; adolescent; anticoagulants;
child; infant; pediatrics; phenprocoumon.
Introduction
Vitamin-K antagonists (VKAs) are used in children to
treat or prevent thromboembolic events [1]. Other than
those seen in adults, pediatric indications are dominated
by congenital heart disease and its complications. World-
wide, warfarin is the most prescribed VKA. Therefore,
most VKA-related research was focused on the use of
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warfarin in adults. However, in several countries, includ-
ing the Netherlands, Germany and Spain, acenocoumarol
and/or phenprocoumon are used.
In relation to the pharmacokinetics and pharmacody-
namics of drugs, it is commonly known that children can-
not be considered as small-sized adults [2]. The metabolic
and hemostatic systems are still in development, which
influences the response to VKAs. Most knowledge on the
kinetics and effectiveness of VKAs is obtained from adult
patients. As a result, guidelines on the use of VKAs in
children are based on relatively low-grade-quality evi-
dence [1,3,4]. This makes it challenging to assess the
required dose of VKAs in children, which can impair the
quality, effectiveness and safety of the treatment.
The percentage of time in the therapeutic international
normalized ratio (INR) range (TTR) is a frequently used
parameter for the quality of VKA treatment. Anticoagu-
lation is stated to be poor when the TTR is below 60–
65%, because below this range VKAs and antiplatelet
therapy have been shown to result in similar antithrom-
botic effectiveness in a population of adult patients with
atrial fibrillation [5]. When the TTR is above 70% the
anticoagulation control is defined as high by the Euro-
pean Society of Cardiology [6]. These definitions of anti-
coagulation control are all based on studies in adults.
Considering there is no information available for pedi-
atric patients, this is currently the only definition that can
be used to classify the quality in pediatric patients.
The reported TTR in children using a VKA, mostly
warfarin, varies between 39 and 92.9% [7–14]. The level
of the TTR is largely dependent on differences in patient
populations (i.e. age and genetic composition) and the
management of VKA therapy (patient self-testing, patient
self-management [self-testing and self-dosing], manage-
ment by an anticoagulation clinic or general care strate-
gies) [7,15]. Moreover, other factors play a role, such as
the method of calculating the TTR, the type of VKA, if
the TTR includes the initiation period of the VKA or not
and the predefined therapeutic INR range (TR) [16–18].
This article presents the characteristics from the Chil-
dren Anticoagulation and Pharmacogenetics Study
(CAPS). Up to now acenocoumarol and phenprocoumon
have not been widely studied in children. We assessed the
quality, safety and effectiveness during the first year of
acenocoumarol and phenprocoumon treatment in the
Netherlands.
Methods
Study design
The study protocol from CAPS was approved by the
UPPER Institutional Review Board of the Division of
Pharmacoepidemiology and Clinical Pharmacology of
Utrecht University. CAPS is a multicenter retrospective
follow-up study in four pediatric hospitals in Amsterdam,
Utrecht, Rotterdam and Groningen, and the Leiden anti-
coagulation clinic, in the Netherlands. CAPS was
designed to study the pharmacogenetics of acenocoumarol
and phenprocoumon in children. Children aged 18 years
or younger, who used one of the two VKAs after 1 Jan-
uary 1995, were invited to participate. Patients (and/or
their parents or legal guardians if appropriate for the age
of the patient) who provided written informed consent
were eligible for participation. The follow-up of a patient
ended at the date of data collection at the anticoagulation
clinic (between 11 January 2014 and 10 March 2016),
when they became 19 years of age, when they stopped
VKA therapy or when they were lost to follow-up. For
these first analyses only the first year of use was taken
into account. Patients were excluded from these analyses
when the start date of VKA use was unknown or when
no (valid) INR information was available within the first
year. All data were collected using a digital form in the
study database. No standardized method for information
collection was available, because every hospital had a
somewhat different system for storing the data (on paper/
electronically). INR values, dosing information, indica-
tion, TR and weight and height were all retrospectively
collected from the patient records of the hospital and the
anticoagulation clinic(s) managing the VKA therapy of
the patient. Furthermore, information was collected at
the time that the informed consent was given by a short
patient questionnaire, including questions about weight
and height at the start of VKA use.
Quality assessment
For primary assessment of the quality of treatment, only
patients using acenocoumarol or phenprocoumon for the
first time during follow-up were included. To assess the
quality of treatment, four parameters were calculated: the
time to an INR in TR, TTR and the percentage of time
below and above TR. Additionally, the number of INR
measurements and the number of dose changes of more
than 10% in mean daily dose between two INR measure-
ments were calculated. The parameters were calculated
for the first month and every 3 months during the first year
of treatment. Patients had to fulfil the criteria specified in
Table 1 to be included in the calculation of the specified
parameter. The TTR was calculated using the Rosendaal
method [19]. This method assumes linearity between two
INR measurements. When there were 28 days or more
between two INR measurements, linearity was no longer
assumed and the time between these two INR measurements
was not included in the TTR.
Effectiveness and safety assessment
Effectiveness and safety were assessed during the first year
of treatment by the number of INRs below 2 (no thera-
peutic effect expected) or above 6 (increased risk of
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bleeding events [20]), the use of vitamin K, and by
reviewing the free text of the patient’s records at the anti-
coagulation clinics for mention of both clinical or non-
clinical bleeding or thrombotic events. Furthermore, the
hospital records regarding correspondence on outpatient
consultations, discharge letters and clinical notes during a
hospital stay were checked for one of these events.
Thromboembolic events were defined as new (recurrent/
incident) thromboembolic events after the start of war-
farin. Bleeding events were defined as all events describing
an abnormal bleed somewhere in the body. All events
were manually coded as types of event based on the loca-
tion in the body.
Statistical analysis
To compare the characteristics of the acenocoumarol and
phenprocoumon cohorts, a chi-squared test, an indepen-
dent sample t-test or a Mann–Whitney U-test was used.
Spearman correlation, independent sample t-test or one-
way ANOVA were used to assess the associations between
number of INR measurements, number of dose changes of
more than 10%, age, TR, and patient self-testing with the
TTR. Because of the low sample size these analyses were
performed on all patients, without distinguishing between
the two VKAs. Also, the difference in time below, within
and above TR between patients with and without a bleed-
ing event was tested using an independent sample t-test.
The data were analyzed using the statistical software
SPSS version 23.
Results
In total, 573 pediatric patients who used a VKA, were
identified and invited in writing to participate in the
study. We were able to get in contact with 485 patients,
and of these patients, 213 gave informed consent. Of
these patients, 172 started with acenocoumarol, 34 with
Table 1 Criteria for calculating the quality parameters
Time to
INR in TR
TTR + number of INR measure-
ments
Number of dose
changes of > 10%
First
month
Months
1–3
Months 4–6/7
–9/10–12
INR within 5 days x x x – –
No missing dose and INR information for ≥ 7 days during
transition from hospital to anticoagulation clinic
x x x – –
Number of INRs/month required – ≥ 3 ≥ 2 ≥ 1 –
No hospital readmission for surgery – x x – –
≥ 90% of the daily dosages should be available for the specific
period
– – – – x
INR, international normalized ratio; TR, therapeutic INR range; TTR, percentage of time in therapeutic INR range. x, required; –, not
required.
Total selected patients
n = 573
Patients gave informed consent
n = 213
n = 172
n = 155
Unreachable or unwilling to participate
n = 360
Start with warfarin
Start with acenocoumarol
n = 34
Start with phenprocoumon
n = 32
Phenprocoumon cohortAcenocoumarol cohort
n = 17
Excluded
n = 2
Excluded
n = 7
Fig. 1. Flowchart of the patients included in the acenocoumarol and phenprocoumon cohort.
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phenprocoumon and seven with warfarin (see Fig. 1).
Seventeen acenocoumarol and two phenprocoumon
patients were excluded as a result of an unknown start
date and/or no (valid) available INR measurements dur-
ing the first year of VKA use. Furthermore, the seven
patients who started on warfarin were excluded. Table 2
provides an overview of the characteristics of the aceno-
coumarol and phenprocoumon cohorts. The characteris-
tics of the two cohorts differed statistically significantly in
the distribution of age (P = 0.001), indication for VKA
use (P < 0.001) and duration of VKA use (P = 0.005).
An important difference between the two cohorts was the
percentage of patients using the VKA for a cardiac indi-
cation. For acenocoumarol this was 63%; for phenpro-
coumon it was 38%. This difference in indication for
VKA use also had an effect on the duration of use, which
was more than 1 year for 58.1% of patients on aceno-
coumarol and 28.1% of patients on phenprocoumon
(Table 2).
In the first year of the VKA treatment, patient self-test-
ing occurred in 43.3% of patients for acenocoumarol and
34.4% for phenprocoumon. Only a small proportion of
the patients using acenocoumarol (7.7%) had complete
self-management (self-testing and self-dosing).
Quality of treatment
Within 7 days more than two-thirds of the patients had
an INR within TR; within 14 days this percentage
increased to more than 80%. The overall quality of
Table 2 Characteristics of the patients starting acenocoumarol or phenprocoumon therapy
Acenocoumarol (n = 155) Phenprocoumon (n = 32) P-value
Gender (female), n (%) 75 (48.4) 17 (53.1) 0.625
Age at start of VKA use in years, n (%) 0.001
< 1 24 (15.5) 8 (25.0)
1–3 37 (23.9) 7 (21.9)
4–6 22 (14.2) 1 (3.1)
7–9 17 (11.0) 0 (0)
10–12 18 (11.6) 0 (0)
13–15 22 (14.2) 5 (15.6)
16–18 15 (9.7) 11 (34.4)
European ethnicity, n (%) 131 (84.5) 29 (90.6) 0.580
Indication for anticoagulation, n (%) <0.001
Fontan procedure 40 (25.8) 5 (15.6)
Prosthetic heart valve 32 (20.6) 0 (0)
Dilated cardiomyopathy 18 (11.6) 7 (21.9)
Deep vein thrombosis/pulmonary embolism 48 (31.0) 13 (40.6)
Aneurysm 4 (2.6) 0 (0)
Pulmonary hypertension 2 (1.3) 0 (0)
Cerebral* 4 (2.6) 2 (6.3)
Prophylactic after surgical procedure† 0 (0) 5 (15.6)
Other cardiac indication‡ 6 (3.9) 0 (0)
Antiphospholipid syndrome 1 (0.6) 0 (0)
BMI at the start of VKA use§, median (IQR) 15.7 (14.2–17.6) 16.4 (15.1–21.1) 0.064
BSA at the start of VKA use§,¶, median (IQR) 0.80 (0.57–1.31) 1.25 (0.61–1.83) 0.109
TR, n (%) 0.770
Extra low (2.0–2.5) 9 (5.8) 2 (6.3)
Low (2.0–3.0) 27 (17.4) 4 (12.5)
Standard (2.0–3.5) 82 (52.9) 21 (65.6)
High (2.5–4.0) 33 (21.3) 5 (15.6)
Extra high (3.5–4.5 [5]) 4 (2.6) 0 (0.0)
Duration of use, n (%) 0.005
< 3 months 20 (12.9) 10 (31.3)
3–6 months 33 (21.3) 8 (25.0)
6–12 months 10 (6.5) 3 (9.4)
>1 year 90 (58.1) 9 (28.1)
Unknown 2 (1.3) 2 (6.3)
Patient self-testing, n (%) 67 (43.3) 11 (34.4) 0.433
Patient self-monitoring, n (%) 12 (7.7) 0 (0) 0.225
Switching between VKA, n (%) 17 (11.0) 2 (6.3) 0.167
VKA, vitamin K antagonist; BMI, body mass index; IQR, interquartile range; BSA, body surface area; TR, therapeutic international normal-
ized ratio range. *Consists of sinus thrombosis (n = 3), cerebrovascular accident (n = 2), and cerebrovascular insufficiency with brainstem
infarction (n = 1). †Consists of prophylactic use after a stent placement (n = 2) or orthopedic surgery (n = 3). ‡Consists of supraventricular
tachycardia (n = 3), arrhythmia (n = 1), Blalock-Taussig shunt (n = 1) and impaired left ventricular function (n = 1). §Known for n = 151
(acenocoumarol) and n = 29 (phenprocoumon) patients. ¶Calculated using the formula of Haycock.
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treatment, as expressed by the TTR, was 47.0% and
51.4% for users of acenocoumarol and phenprocoumon,
respectively, during the first month of treatment (Fig. 2).
When considering the first 3 months of treatment the
TTR was 54.6% for acencocoumarol and 63.0% for
phenprocoumon. After the first 3 months of treatment
the TTR ranged between 64.7% and 69.1% for aceno-
coumarol and 65.8% and 75.4% for phenprocoumon in
the 3-month periods thereafter. At the beginning of treat-
ment, when out of TR, time was most often spent below
TR. Later in treatment, this was shifting to a more equal
division of the time out of TR between above and below
TR (Fig. 2).
During the first month a large number of INR mea-
surements was carried out (more than twice each week).
In the months thereafter, this decreased to less than once
a week. The frequency of dose changes of more than
10% decreased over time, from a median of 2.3 (aceno-
coumarol) and 3.2 (phenprocoumon) dose changes per
month in the first 3 months to less than one dose change
per month in the last 3 months of the first year (Table 3).
The TTR was negatively correlated (P < 0.05) with the
number of INR measurements in the first 9 months of
VKA treatment and with the number of dose changes
during the first year (Table S1). For age, a positive corre-
lation existed with the TTR in the first 3 months
(r = 0.398, P < 0.001). In the rest of the first year of
VKA treatment this effect was less clear, but there was
still a trend towards a higher TTR with increasing age
(Table S1). There was a trend for higher mean TTRs in
patients who used patient self-testing compared with
patients who were tested by an anticoagulation clinic.
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Fig. 2. The mean percentage of time below, within and above therapeutic INR range within the first month and months 1–3 (Q1), months 4–6
(Q2), months 7–9 (Q3) and months 10–12 (Q4) of the first year of acenocoumarol (left) and phenprocoumon (right) treatment. INR, interna-
tional normalized ratio; Q, quarter.
Table 3 Treatment quality during the first year of treatment with acenocoumarol and phenprocoumon
Acenocoumarol n = 155 Phenprocoumon n = 32
Achieving TR
≤ 7 days, n (%)* 106 (76.3)
139
21 (67.7)
31
≤ 14 days, n (%)* 131 (94.2) 27 (87.1)
Number of days, median (IQR) 4.0 (2.0-7.0) 4.0 (3.0-12.0)
Number of INRs per month, median (IQR)
< 1 month 10.0 (7.0–13.0) 110 9.0 (7.0–12.0) 30
Months 1–3 6.0 (4.7–7.7) 101 6.2 (4.3–10) 26
Months 4–6 3.7 (2.7–4.3) 94 4.3 (2.3–5.0) 19
Months 7–9 3.3 (2.5–4.3) 80 4.3 (2.0–4.3) 11
Months 10–12 3.0 (2.3–4.0) 77 2.7 (2.0–3.3) 6
Number of dose changes >10% per month, median (IQR)
Months 1–3 2.3 (1.3–3.3) 152 3.2 (1.7–4.0) 32
Months 4–6 0.8 (0.3–2.0) 110 0.7 (0.3–3.0) 21
Months 7–9 0.7 (0.3–1.7) 91 1.0 (0.0–2.7) 14
Months 10–12 0.7 (0.0–1.3) 81 0.3 (0.0–1.0) 11
INR, international normalized ratio; TR, therapeutic INR range; IQR, interquartile range. *The percentages are based on the number of
patients fulfilling the criteria for the parameter during that specific period, not on the total cohort.
© 2017 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on Thrombosis and Haemostasis.
Quality of oral anticoagulant therapy in children 5
Only for months 7 to 9 was the difference (12%) statisti-
cally significant (Table S2). There was a statistically sig-
nificant difference (P < 0.001) between the TTR and the
different TRs (Table S3). The patients with an extra low
(2.0–2.5) or high (3.5–4.5/5) TR had a lower TTR com-
pared with patients with a standard TR (2.0–3.5), which
persisted throughout the year (Fig. 3).
Effectiveness and safety of treatment
During the first year of follow-up no (recurrent) throm-
boembolic events occurred. Bleeding events were quite
common for both VKAs. They occurred at least once in
14.8% of the patients using acenocoumarol and in 31.3%
of the patients using phenprocoumon (Table 4). The most
commonly reported bleeding events were nosebleeds and
(unexplained) bruising. None of the events could be
explained by an INR value above 6 at the last measure-
ment before the event. However, there seems to be a
trend that patients with a bleeding event over the first
year of treatment had a higher or equal percentage
within, a lower or equal percentage below and a higher
or equal percentage of time above therapeutic range com-
pared with patients without a bleeding event (Table S4).
Only in the third quarter of the first year was the percent-
age of time below therapeutic range statistically
0
TR group
n =
2.0-2.5
7
2.0-3.0
22
2.0-3.5
69
2.0-4.0
26
3.5-4.5(5.0)
3
TR group
n =
2.0-2.5
5
2.0-3.0
20
2.0-3.5
36
2.5-4.0
19
3.5-4.5(5.0)
3
20
40
60
TT
R
 d
ur
in
g 
1s
t q
ua
rte
r (
%)
80
100
A B
0
20
40
60
TT
R
 d
ur
in
g 
4t
h 
qu
ar
te
r (
%) 80
100
P = 0.005
P = 0.003
P = 0.001
P = 0.006
P = 0.018
P = 0.001
P = 0.038
P < 0.001
P = 0.013
Fig. 3. Percentage of time in therapeutic INR range (TTR) by therapeutic range (TR) among users of acenocoumarol and phenprocoumon
combined. (Α) During the first 3 months of vitamin K antagonist (VKA) use. (Β) During the last 3 months of the first year of VKA use.
Table 4 Effectiveness and safety parameters during the first year of acenocoumarol and phenprocoumon treatment.
Acenocoumarol (n = 155) Phenprocoumon (n = 32)
n (%) Mean rate*
Mean fraction
of total INRs‡, % n (%) Mean rate*
Mean fraction
of total INRs‡, %
Thromboembolic events 0 0 – 0 0 –
Bleeding events 23 (14.8) 1.35 – 10 (31.3) 1.50 –
Type of bleeding event
Nosebleed 13 (8.4) 4 – 2 (6.3) 2 –
Bruising with unknown
cause
7 (4.5) 2 – 1 (3.1) 1 –
Increased bruising on
impact
5 (3.2) 1 – 2 (6.3) 2 –
Hematuria 2 (1.3) 1 – 0 0 –
Blood in stool (melena) 1 (0.6) 1 – 1 (3.1) 1 –
Hematemesis 0 0 – 1 (3.1) 1 –
Eye bleeding 0 0 – 1 (3.1) 1 –
Other† 0 0 – 3 (9.4) 1 –
INR <2 153 (98.7) 8.96 33.2 30 (93.8) 8.93 28.3
INR >6 90 (58.1) 2.03 7.9 11 (34.4) 1.45 4.0
Use of vitamin K 13 (8.4) 1.15 – 11 (34.4) 1.18 –
INR, international normalized ratio; n, number of patients experiencing at least one event; –, not applicable. *For type of bleeding event the
maximum rate is shown instead of the mean rate. †Consists of bleeding at an implantable cardioverter-defibrillator (n = 1) and prolonged
bleeding after injury (n = 2). ‡Fraction of INR < 2 or > 6 of the total INR measurements of a patient.
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significantly lower in the patients with a bleeding event
compared with the patients without a bleeding event
(P = 0.001).
Although there were no (recurrent) thromboembolic
events during the first year, more than 90% of the
patients experienced at least once an INR of less than 2
(Table 4). For both VKAs around one-third of the total
number of INRs per patient was below 2. INRs higher
than 6 occurred less frequently. These were present at
least once in 58.1% and 34.4% of the acenocoumarol
and phenprocoumon users, respectively. Furthermore,
these INRs made up a small fraction of the total INRs
per patient (7.9% for acenocoumarol and 4.0% for
phenprocoumon). Not all INRs above 6 resulted in vita-
min K administration. Only 8.4% of the patients were
treated with vitamin K in the acenocoumarol cohort,
which was statistically significantly (P < 0.001) lower
than the 34.4% of the patients in the phenprocoumon
cohort.
Discussion
The study shows that the quality (defined as the TTR) of
VKA treatment in pediatric patients in the Netherlands is
acceptable after the first 3 months of use. The TTR ran-
ged between 64.7% and 69.1% for acenocoumarol and
65.8% and 75.4% for phenprocoumon. However, the
TTR was lower during the first month ( 50%). Further-
more, the frequency of INR measurements and dose
changes of more than 10% was high during the first 3
months of VKA treatment. Although the INR was fre-
quently out of range and also in the extreme areas (< 2
and > 6), this was not associated with bleeding or throm-
boembolic events. However, a large proportion of the
patients (14.8% for acenocoumarol and 31.3% for phen-
procoumon) still had at least one bleeding event during
the first year. No thromboembolic events were reported.
In adults, high (above 4–5) or low (below 2) INRs are
correlated with major bleedings and thromboembolic
events, respectively [20]. We were not able to find such
associations. However, we did see that patients with
bleeding events tended to have more time above range
and less time below range, mostly not statistically signifi-
cant, compared with patients without a bleeding event.
However, because of the low number of events we didn’t
have enough power to study this. The number of compli-
cations could have been higher. Because of the retrospec-
tive nature of the study such complications may not have
been retrieved. Another possibility is that events were pre-
vented because of the intensive monitoring policy of the
anticoagulation clinics with children on VKAs. In our
cohort, INR measurements were carried out more often
(three INR measurements/month) than recommended in
the adult ACCP guideline of one INR measurement per
4–12 weeks [21], and the minimum of one INR measure-
ment per month recommended for children [4]. This
allows rapid dose adjustments when needed. Furthermore,
the hemostatic system is still developing during childhood
[22]. This might well be related to differences in risks of
bleeding and thromboembolic events in comparison to
adults.
Our TTRs were mostly higher (47–75.4%) than the
TTRs found by Spoor et al. of just under 50% during the
first year of treatment in children using acenocoumarol
and phenprocoumon in the Netherlands [11]. A possible
explanation for this difference is the larger proportion of
patients in their cohort with a duration of follow-up/use
of less than 3 months (46% compared with 16% in our
cohort). In the first months, INR values show more fluc-
tuation than in later periods, which reduces the overall
TTR. This is also supported by our TTRs in the first
month/first 3 months, which were around 50%. The
TTRs of 65–75% after the first 3 months of treatment in
our study are similar to the overall TTR of 63% found in
the similar warfarin cohort of Biss et al. [8]. Our TTRs
during the different time periods after the start of VKA
therapy are also similar to the TTRs found in adults,
changing from 54% in the first month to 75% after the
first 3 months [23].
As expected, there was a clear association between the
TR and the TTR during the first year. The TTR in the
lower and narrower TR of 2.0–2.5 and the higher TR of
3.5–4.5 (5.0) were significantly lower compared with the
TTR in children with a TR of 2.0–3.5. This is in line with
the findings of previous studies in adults [17,18]. The study
by Meier et al. showed that a narrow TR of 2.0–2.5 led to
more INRs below 2 compared with a TR of 2.0–3.0 [18].
Gadisseur et al. showed that a TR of 2.5–3.5 resulted in a
significantly higher TTR than a TR of 3.0–4.0 [17]. How-
ever, for both extreme TRs the numbers of patients were
very low in our cohort. Furthermore, it is possible that
patients were dosed with the aim of achieving a different
TR than the one stated in the patient record, which reduces
the calculated TTR. Interestingly, patients with the same
indication often had different TRs stated in the patient
records (data not shown). This indicates that possibly indi-
vidual patient characteristics or the preference of the physi-
cian has an influence on the choice of the TR.
Although the TTR was on average indicative of an
acceptable anticoagulation control, the standard deviation
was large for both VKAs. For patients with low TTRs it
is important to identify the causes (patient-specific and/or
management-related factors) and to search for a way to
improve these TTRs. Although we did not find any
thromboembolic events in the first year, we did find that
a large proportion of patients experienced bleeding
events. Furthermore, the very frequent INR measure-
ments and dose changes of more than 10% were common
in the patients with lower TTRs, which can impair patient
satisfaction and increase costs.
Earlier studies have shown that patients who self-test
and self-manage can improve quality of life, patient
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satisfaction and TTR [12,14,24]. As a result of the large
standard deviations of the TTRs, we only found a statisti-
cally significant association between patient self-testing
and the TTR during the seventh to ninth months of use.
However, there was a clear trend of higher TTRs after
the first 3 months for patients who were self-testing their
INRs. Involving patients in their anticoagulation control
by self-testing or self-management might be a way to
improve the TTR, especially during the maintenance
phase.
A meta-analysis of all randomized controlled trials in
adults has shown that using a pharmacogenetic dosing
algorithm increases the TTR, especially in the first
months of use [25]. No such pediatric dosing algorithm
exists yet for acenocoumarol and phenprocoumon. With
the data from CAPS we will develop a pediatric pharma-
cogenetic-guided dosing algorithm for both VKAs. With
this model it will be easier to predict the appropriate
starting dose for individual patients, which might reduce
the number of INR measurements and dose changes and
increase the TTR.
A limitation of this study was the small number of
patients, especially for phenprocoumon. Phenprocoumon
is far less frequently used as a first VKA in pediatric
patients in the Netherlands compared with aceno-
coumarol. Furthermore, the retrospective data collection
might have resulted in incomplete or misinterpretation of
data. With the available data we were not able to study
the cause of low TTRs, such as diet, fever and/or concur-
rent drug therapy. Some information about concurrent
drug therapy was available, but was too incomplete to
use in the analysis. A strength of our study is that our
cohort was composed of patients from different sites in
the Netherlands, making it a representative sample of the
Dutch pediatric population using VKAs. With the pro-
vided information on patient and treatment characteris-
tics, physicians from other countries should be able to
translate the results to their own situation.
In conclusion, the overall quality of acenocoumarol
and phenprocoumon treatment in pediatric patients in the
Netherlands is acceptable, but can be improved. Espe-
cially during the first month, the quality of VKA treat-
ment is low, and during the first year of treatment a
substantial number of bleeding events occurs. Developing
a dosing algorithm can improve VKA anticoagulation
and increase patient satisfaction, with fewer INR mea-
surements, dose adjustments and possibly bleedings.
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